On this basis, the selective killing of M2 macrophages by RAPA is not unexpected. In fact, we previously reported that in resting human monocytes, cell activation through three different signal pathways prevents death resulting from RAPA treatment: Ivacaftor manufacturer GM-CSF/IL-3 receptors, TLR4 and IL-1β/TNF-α/IFN-γ receptors.[28]

As levels of IL-3, IFN-γ, IL1-β and TNF-α are all significantly higher in M1 than in M2 polarization, this can explain the M1 resistance to RAPA induced apoptosis. M1-polarized macrophages mediate resistance to intracellular pathogens and tissue destruction whereas M2-polarized cells are generally oriented to tissue remodelling and repair.[42] The target of RAPA action is the inhibition of mTOR, so our findings propose that the mTOR pathway is essential

in learn more M2 but not in M1 macrophage survival. The mTOR acts as a central sensor for nutrient/energy availability[10] and it could provide an important homeostatic mechanism for controlling the number and the function of M1 and M2 macrophages in a manner dependent upon basal nutritional status. On this basis, we can speculate that in the presence of sufficient nutrients and energy, mTOR could relay a permissive signal for M2 survival, facilitating events that drive tissue remodelling and repair. On the other hand, in conditions of limited nutrient availability, as mimicked by RAPA treatment, mTOR could preferentially ‘sacrifice’ the M2 compartment, so preserving the resistance to pathogens due to the existence of mTOR-independent pathways that regulate M1 survival at the site of inflammation. Consistent with this hypothesis is the finding that RAPA treatment impairs wound healing in patients.[43] Moreover the relevance in regulating M2 survival could add a further explanation to activity of RAPA against cancer[44] and atherosclerosis development,[45] two diseases supported also by the presence of alternative activated macrophages.[46-48] In accordance with this, Chen et al.[49] recently reported that the selleck chemicals mTOR pathway is a critical element in the regulation of monocyte differentiation

to tumour-associated macrophages and that inhibition of mTOR by RAPA reduced tumour growth both in vitro and in vivo by modulating macrophage polarization. Beyond the impact on M2 survival, RAPA induced relevant modification of macrophage phenotype and cytokine/chemokine secretion in vitro. M1 macrophages appeared more affected than M2 and, as a general trend, RAPA unbalanced the system to classic activation. In fact, in M1 macrophages, RAPA increased the expression of CD86 and CCR7 and induced a significantly higher release of IL-6, TNF-α and IL-1β (markers of classic activation) while reducing the expression of CD206 and CD209 and the release of IL-10, VEGF and CCL18 (markers of alternative activation).